Point72 Asset Management L.P. grew its position in Global Blood Therapeutics, Inc. (NASDAQ:GBT) by 189.5% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 2,022,700 shares of the company’s stock after purchasing an additional 1,323,934 shares during the quarter. Point72 Asset Management L.P. owned approximately 4.63% of Global Blood Therapeutics worth $62,805,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. State Street Corp boosted its stake in Global Blood Therapeutics by 217.9% during the second quarter. State Street Corp now owns 2,138,323 shares of the company’s stock worth $58,479,000 after acquiring an additional 1,465,595 shares in the last quarter. Janus Henderson Group PLC bought a new position in Global Blood Therapeutics during the second quarter worth $26,919,000. BlackRock Inc. boosted its stake in Global Blood Therapeutics by 30.0% during the second quarter. BlackRock Inc. now owns 3,404,538 shares of the company’s stock worth $93,114,000 after acquiring an additional 785,691 shares in the last quarter. Vanguard Group Inc. boosted its stake in Global Blood Therapeutics by 15.7% during the second quarter. Vanguard Group Inc. now owns 2,933,251 shares of the company’s stock worth $80,224,000 after acquiring an additional 397,271 shares in the last quarter. Finally, Perceptive Advisors LLC boosted its stake in Global Blood Therapeutics by 8.4% during the third quarter. Perceptive Advisors LLC now owns 4,264,066 shares of the company’s stock worth $132,399,000 after acquiring an additional 330,139 shares in the last quarter. 90.48% of the stock is currently owned by institutional investors.

In related news, Director Charles J. Homcy sold 70,000 shares of the firm’s stock in a transaction dated Friday, October 27th. The shares were sold at an average price of $33.97, for a total transaction of $2,377,900.00. Following the completion of the sale, the director now owns 83,328 shares in the company, valued at $2,830,652.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Jung Choi sold 3,000 shares of the firm’s stock in a transaction dated Friday, September 29th. The stock was sold at an average price of $30.00, for a total transaction of $90,000.00. Following the sale, the insider now owns 140,055 shares of the company’s stock, valued at approximately $4,201,650. The disclosure for this sale can be found here. In the last quarter, insiders sold 88,500 shares of company stock valued at $3,003,350. 5.30% of the stock is currently owned by corporate insiders.

Shares of Global Blood Therapeutics, Inc. (NASDAQ GBT) opened at $45.70 on Monday. Global Blood Therapeutics, Inc. has a 1-year low of $13.35 and a 1-year high of $45.75.

Global Blood Therapeutics (NASDAQ:GBT) last announced its earnings results on Thursday, November 2nd. The company reported ($0.66) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.62) by ($0.04). During the same quarter in the prior year, the firm posted ($0.58) EPS. analysts forecast that Global Blood Therapeutics, Inc. will post -2.55 earnings per share for the current fiscal year.

Several research analysts recently issued reports on the stock. Wedbush reissued an “outperform” rating and set a $73.00 target price on shares of Global Blood Therapeutics in a research note on Monday, December 4th. BidaskClub upgraded shares of Global Blood Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, September 27th. ValuEngine downgraded shares of Global Blood Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Cowen restated an “outperform” rating and set a $83.00 price objective on shares of Global Blood Therapeutics in a report on Monday, August 14th. Finally, HC Wainwright began coverage on shares of Global Blood Therapeutics in a report on Friday, December 1st. They set a “buy” rating and a $73.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, one has given a hold rating and fourteen have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $56.38.

COPYRIGHT VIOLATION NOTICE: “Point72 Asset Management L.P. Has $62.81 Million Stake in Global Blood Therapeutics, Inc. (GBT)” was first published by Watch List News and is owned by of Watch List News. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of international trademark and copyright legislation. The original version of this news story can be read at https://www.watchlistnews.com/point72-asset-management-l-p-has-62-81-million-stake-in-global-blood-therapeutics-inc-gbt/1756810.html.

About Global Blood Therapeutics

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).

Want to see what other hedge funds are holding GBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Global Blood Therapeutics, Inc. (NASDAQ:GBT).

Institutional Ownership by Quarter for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.